Gene Solutions Advances Precision Oncology at Singapore Meeting

Gene Solutions presented significant advancements in cancer care during the Singapore Society of Oncology Annual Scientific Meeting 2025 (SSO ASM 2025) on October 15, 2025. The focus was on how Molecular Residual Disease (MRD) testing and AI-driven multi-omics technologies can shift cancer treatment from a reactive to a proactive approach. This event highlighted Singapore’s growing reputation as a central hub for innovation and collaboration in the healthcare sector across the Asia-Pacific region.

Exploring the Future of Oncology

The symposium, titled “Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors,” gathered a distinguished group of oncologists and molecular biology experts. They discussed how analyzing circulating tumor DNA (ctDNA) through MRD assays can enhance cancer monitoring at the molecular level. Experts explored the potential of this innovative method to provide earlier detection of cancer recurrence and more personalized treatment strategies.

Gene Solutions is distinguished by its comprehensive platform that integrates DNA, RNA, and AI-enhanced multi-omics signals. This multi-omics approach aims to improve the sensitivity of ctDNA detection, uncover complex gene fusions, and assist in predicting the locations of primary tumors. Such advancements are crucial for delivering personalized treatment decisions that can significantly impact patient outcomes.

Recent studies published in JCO Oncology Advances and npj Breast Cancer underscore the effectiveness of ctDNA-based MRD testing. These studies suggest that MRD testing can predict early recurrence and support cost-effective monitoring strategies in practical settings. With its CAP-accredited laboratory in Singapore and a global network, Gene Solutions is committed to fostering scientific collaboration that enhances genomic research and precision oncology throughout the Asia-Pacific.

A Call for Collaborative Efforts

Ida Deleskog Lindstroem, Global Medical Affairs Director at Gene Solutions, emphasized the potential of MRD and multi-omics platforms. She stated, “Molecular residual disease (MRD) and multi-omics platforms show promise in advancing precision oncology by enabling clinicians to detect cancer recurrence earlier and tailor treatments more effectively.” Lindstroem called upon oncologists, researchers, and healthcare partners in the Asia-Pacific region to join efforts in advancing these technologies, enhancing data-driven, personalized care that aims to improve patient outcomes across diverse healthcare systems.

For more details about the symposium and its highlights, visit the official Gene Solutions page at [Gene Solutions News](https://genesolutions.com/news/gene-solutions-showcases-mrd-and-multi-omics-advances-at-sso-asm-2025-in-singapore).

About Gene Solutions

Gene Solutions is a multinational biotechnology company dedicated to advancing genetic testing and research throughout the Asia-Pacific region. By leveraging Next-Generation Sequencing (NGS) and Artificial Intelligence, the company provides an extensive portfolio of advanced solutions. With over two million genetic tests conducted to date, Gene Solutions is recognized for its proprietary research, CAP-accredited laboratories, and contributions to the evolution of precision medicine through clinical studies and regional collaborations.